BCBSRI to cover Cologuard

PROVIDENCE – Exact Sciences Corp. has entered into an agreement effective Sept. 15 with Blue Cross Blue Shield of Rhode Island to include Cologuard, a screening test for colon cancer, under its commercial and Medicare Advantage plans.

“We look forward to working with BCBS of Rhode Island to provide their members with a new option for colon cancer screening. Colon cancer is most treatable when caught early, highlighting the importance of routine screening,” Kevin Conroy, chairman and CEO of Exact Sciences in Madison, Wis., said in a statement. “The growing coverage of Cologuard during the first year of launch underscores the strength of our clinical data and the demand for more noninvasive screening options in order to improve colon cancer screening rates across the country.”
According to Exact Sciences Corp., Cologuard is the only FDA-approved noninvasive stool-based DNA screening test for colon cancer.
The test will be available without a co-payment or co-insurance to BCBSRI members through their doctor, the company said.
Information from Exact Sciences said that Cologuard offers people 50 years and older at average risk for colorectal cancer a screening test that they can do in the privacy of their own home. Cologuard is available by prescription only.

No posts to display